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AbstrAct
Indoleamine 2,3-dioxygenase (IDO) catalyzes the degradation of tryptophan, 
which plays a critical role in immune suppression through regulating the production 
of a series of metabolites that are generally referred to as kynurenines. It has become 
increasingly clear that epithelial cells (ECs) play an active role in maintaining lung 
homeostasis by modulating the function of immune cells via producing cytokines, 
chemokines, and anti-microbial mediators. In this study we assessed the regulation 
of IDO activity and expression in human primary ECs and EC lines under steady state 
conditions and in response to bacterial and allergenic stimuli. We also investigated 
the potential immune modulatory functions of IDO expression in human airway ECs. 
Our data clearly show that airway ECs produce IDO, which is down-regulated in 
response to allergens and TLR ligands while up-regulated in response to IFN-γ. Using 
gene silencing, we further demonstrate that IDO plays a key role in the EC-mediated 
suppression of antigen-specific and polyclonal proliferation of T cells. Interestingly, 
our data also show that ECs lose their inhibitory effect on T cell activation in response 
to different TLR agonists mimicking bacterial or viral infections. In conclusion, 
our work provides an understanding of how IDO is regulated in ECs as well as 
demonstrates that “resting” ECs can suppress T cell activation in an IDO dependent 
manner. These data provide new insight into how ECs, through the production of IDO, 
can influence downstream innate and adaptive responses as part of their function in 
maintaining immune homeostasis in the airways.
IntroductIon
Epithelial cells (ECs) are the first line of defense 
against airborne pathogens and allergens. ECs modulate 
immune responses by regulating the expression of 
different pattern recognition receptors and via their 
own ability to produce a plethora of cytokines and 
chemokines. Furthermore, it is well established that 
the cross-talk between ECs and dendritic cells (DCs) 
is very important in orchestrating immune responses to 
airborne antigens. In this context, ECs have been shown to 
directly and indirectly modulate T cell responses [1, 2]. In 
particular, airway ECs can influence T cell activation and 
differentiation by increasing the recruitment, maturation, 
and activation of DCs through the secretion of diverse 
chemokines [3-5] and cytokines [6, 7]. For example, 
murine colonic [8] and lung [9, 10] ECs are able to inhibit 
antigen presenting cell-induced T cell proliferation. This 
effect appears to be cell-cell contact-dependent [8-10], 
and was found to be attenuated by pre-treatment of ECs 
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with IL-4 [10] or after viral infection [9]. In addition, it 
has been suggested that direct contact between ECs and 
DCs is essential to inhibit in vitro T cell responses against 
allergens [11]. However, despite some evidence suggesting 
a role for TGF-β in decreasing T cell proliferation to some 
extent, the exact mechanism underlying such EC-mediated 
suppression of T cell responses has remained elusive [9]. 
Tryptophan (TRP) is an essential amino acid for the 
synthesis of proteins and neurotransmitters as well as for 
cell growth and function [12]. In mammals, the primary 
route of TRP degradation into kynurenines (KYNs) is 
controlled by extra-hepatic indoleamine 2,3- dioxygenase 
(IDO) and hepatic tryptophan 2,3-dioxygenase. There 
are two IDO isoforms, IDO1 and IDO2 [13-15], and 
these isozymes exhibit different expression patterns and 
molecular regulation [12, 15, 16]. However, the function 
of IDO1 (herein referred to as IDO) has been more 
extensively analyzed and was shown to have diverse 
immune-regulatory properties [17, 18]. TRP depletion 
as well as TRP-derived metabolites can impact T cell 
activation by inducing apoptosis, activating the stress-
response kinase GCN2, or promoting tolerance through 
activation of the aryl-hydrocarbon receptor [19, 20]. DCs 
express high levels of IDO in response to different stimuli, 
including cytokines such as type-I and type-II IFNs, co-
stimulatory molecules, and TLRs [21]. IDO is highly 
expressed in the immune cells; however, non-immune 
cells, including ECs, have also been shown to express 
functional IDO [22]. Previous work has shown an increase 
in IDO activity and expression (at the mRNA level) in 
human cervical ECs (HeLa cells) after stimulation with 
IFN-γ [23, 24]. This effect was further enhanced in the 
presence of IL-1 or TNF-α, but not in response to LPS 
stimulation. Furthermore, it was demonstrated that diverse 
epithelial carcinoma cell lines [25-27] and primary ECs 
[28, 29] express IDO after IFN-γ treatment. In addition, 
functional IDO expression has been reported to be high 
in the lung [30]. More recently, it was demonstrated that 
Aspergillus fumigatus spores induced the up-regulation 
of IDO in corneal ECs, suggesting the involvement of 
IDO from ECs in the immune responses against fungal 
infections [31].
The aim of this study was to investigate the 
regulation of IDO expression and activity in airway 
cancerous and non-cancerous ECs in response to TLR 
agonists and allergen extracts; and to investigate the 
potential role of EC-derived IDO in the regulation of T 
cell activation. 
results
Human airway ecs inhibit t cell activation in a 
contact-independent manner
Previous studies have demonstrated that murine ECs 
are able to inhibit T cell proliferation [8-10]. Here, we first 
evaluated whether human airway ECs can inhibit T cell 
proliferation. 
ECs cultured on the apical side of a transwell 
membrane, were co-cultured with PBMCs (with no cell-
cell contact) followed by stimulation with either PPD 
or anti-CD3 and CD28 Abs; and T cell proliferation 
was quantified after 3-6 days. The presence of ECs 
significantly suppressed PBMC proliferation (Figure 1A) 
Figure 1: Inhibition of PBMC proliferation and IFN-γ production by human airway epithelial cells (ECs). A. Airway 
ECs (Calu-3) were co-cultured with PBMCs stimulated with 5 μg/ml of tuberculin purified protein derivate (PPD) without cell-cell contact 
(carried out in transwells® with a 0.4-μm pore size). After six days, cell proliferation was assessed. B. IFN-γ concentration in culture 
supernatants. usPBMC= unstimulated PBMC, Data show mean ± SEM from three independent experiments. ****p < 0.0001.
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and IFN-γ production (Figure 1B). We also performed the 
same experiments using a co-culture of DCs and purified 
T cells, which showed a similar level of suppression of T 
cell proliferation in the presence of ECs (data not shown). 
stimulation of ecs with tlr3 and tlr4 ligands 
ameliorates their ability in suppressing t cell 
activation
We next investigated whether TLR agonists, 
simulating bacterial or viral infections, modulated the 
observed inhibitory effect of airway ECs on T cell 
activation. Therefore, we exposed airway ECs to TLR4 or 
TLR3 ligands (LPS and polyI:C, respectively) followed 
by their co-culture with anti-CD3/CD28-stimulated 
PBMCs. After three days, the cells were collected for a 
BrdU proliferation assay and the supernatant was collected 
for cytokine analysis. LPS and polyI:C treatment of ECs 
led to a clear reduction in their ability to suppress T cell 
proliferation compared with the control (Figure 2A). 
The degree of this effect correlated with the level of 
IFN-γ production, which showed a significant increase in 
response to LPS stimulation after 24 h and 48 h, and was 
also slightly enhanced in response to polyI:C, although 
this change was not statistically significant (Figure 2B). 
These findings suggest that the ability of ECs to regulate 
T cell activation could be significantly compromised 
following bacterial or viral infections.
tlr4 stimulation down-regulates Ido in human 
airway ecs without compromising cell viability
To test the hypothesis that the inhibition of T cell 
proliferation by ECs could be mediated by IDO, we first 
investigated the levels of IDO expression in ECs before 
and after stimulation with the TLR4 ligand LPS. Initially, 
we used the Calu-3 cell line as a model for human ECs. 
These cells were incubated with increasing concentration 
of LPS (from Escherichia coli) for 24 h, and IDO activity 
and expression were assessed. Significant down-regulation 
in IDO activity was observed (Figure 3A) in response 
to LPS stimulation. This reduction in IDO activity was 
Figure 2: Influence of TLR-activated airway epithelial cells (ECs) on PBMC proliferation. A. Human airway ECs (Calu-3) 
were co-cultured with PBMCs stimulated with 2 μg/ml of anti-CD3 and anti-CD28 in the presence of 10 µg/ml of LPS or polyribocytidylic 
acid (PolyI:C). After three days, proliferation was assessed. B. IFN-γ production in culture supernatants. Data show mean ± SEM from three 
independent experiments. us=unstimulated*p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.
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accompanied by suppression in IDO1 protein (Figure 3B) 
and gene (Figure 3C) expression. LPS from Salmonella 
minnesota had the same effect on IDO activity (data not 
shown). To determine whether cell death contributed to 
the observed reduction in IDO activity, we measured the 
viability of ECs after LPS stimulation using AlamarBlue 
and LIVE/DEAD staining. The data showed comparable 
EC viability before and after LPS stimulation (Figure 3D), 
indicating that the substantial reduction of IDO expression 
was not associated with cellular death. The same pattern 
of a reduction in IDO activity in response to LPS was 
also observed in human primary ECs as well as in a non-
cancerous epithelial cell line (BEAS-2B), highlighting the 
conserved nature of IDO regulation by LPS (Figure 4).
diverse tlr ligands and allergen extracts 
decrease Ido activity and expression in human 
airway ecs
To verify whether IDO downregulation is only 
observed in response to LPS, we next sought to determine 
the impact of other TLR ligands as well as different 
allergen extracts on IDO activity in human airway ECs. 
ECs were incubated for 24 h with 10 µg/ml of various 
TLR ligands or allergen extracts. As shown in Figure 
5, TLR3 (polyI:C), TLR2/6 (FSL-1), and TLR9 (CpG) 
engagement markedly inhibited IDO activity. However, 
TLR7 and TLR1/2 ligation with imiquimod and a 
synthetic triacylated lipopeptide (Pam3CSK4) respectively 
did not affect IDO activity levels in ECs (data not shown). 
Furthermore, we found significant inhibition of IDO 
activity in response to different allergen extracts, including 
Bermuda grass pollen (BGP), peanut (PEA), German 
cockroach (GC), house dust mite (HDM) and its purified 
allergen Der p 1 (Figure 5A). The down-regulation of IDO 
activity was also observed in primary ECs in response to 
LPS, CpG, and different allergen extracts (Figure 5B). 
To examine whether the suppression in IDO activity 
was reflected in its expression at the protein level, we 
also quantified IDO1 protein expression levels in ECs 
before and after TLR ligation using western blotting. 
These experiments showed a marked reduction in IDO1 
protein expression in TLR-stimulated ECs compared to 
unstimulated cells (Figure 5C).
Ido contributes to the airway ecs-mediated 
suppression of t cell activation
Previous findings have suggested a role for EC-
produced TGF-β in modulating T cell proliferation [9]. 
However, the exact mechanism by which ECs inhibit T 
cell proliferation remains unclear. We therefore examined 
Figure 3: Down-regulation of indoleamine 2,3-dioxygenase (IDO) in response to LPS stimulation in human airway 
epithelial cells (ECs). A. Human airway ECs were incubated with increasing concentration of E. coli LPS for 24 h and IDO activity 
was assessed (n = 5). B. and C. IDO1 protein and gene expression in airway ECs stimulated with 2 µg/ml of LPS for 24 h, respectively 
(n = 3). D. LIVE/DEAD staining of airway ECs stimulated with LPS (10 μg/ml) for 24 h. Cells treated with 4% formaldehyde were used 
as a control. E. The fluorescence quantification of the LIVE/DEAD staining expressed as percentage of live cells (n = 2). F. AlamarBlue 
fluorescence readouts of airway ECs stimulated with increasing concentrations of LPS for 24 h; cells treated with 4% formaldehyde were 
used as a control (n = 4). Ctl=control Data represent the mean values ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. 
Oncotarget57610www.impactjournals.com/oncotarget
the potential role of IDO in mediating the inhibitory 
effect of ECs on T cells. First, we attempted to block 
IDO activity in ECs/PBMCs co-cultures using 1-methyl 
tryptophan, an IDO-inhibitor. However, given the direct 
effect of 1-methyl tryptophan on PBMCs leading to 
suppression of their proliferation (data not shown), we 
decided to directly target IDO activity in ECs. Thus, we 
generated IDOlow-ECs by knocking down the IDO1 gene 
in ECs using small interfering RNA (siRNA), so that only 
IDO activity was suppressed in ECs. As shown in Figure 
6A, there was a significant decrease in IDO activity and 
IDO1 mRNA levels after gene silencing (i.e., IDOlow) 
compared with the control cells that expressed high 
levels of IDO. Subsequently, we co-cultured the IDOlow-
ECs with anti-CD3-activated PBMCs, and proliferation 
was assessed three days later. Figure 6B shows that, as 
expected, IDO-sufficient ECs significantly inhibited T cell 
proliferation, and this effect was significantly reduced after 
silencing IDO. We also investigated cytokine production 
after 24 h and 48 h. As expected, we observed a significant 
reduction in IFN-γ production in the presence of ECs and 
a partial reconstitution in IFN-γ levels in the presence of 
IDOlow-ECs compared with the control cells (Figure 6C). 
Collectively, these results demonstrated the important 
role of IDO produced by ECs for the inhibition of T cell 
activation. 
dIscussIon
ECs are one of the main cellular components 
of the innate immune system, which provide primary 
protection against airborne pathogens and allergens. 
Previous studies have shown that ECs can directly regulate 
conventional and unconventional T cell responses [8, 9, 
32, 33]; however, the molecular basis of such regulation 
has remained elusive. We hypothesized that airway ECs 
modulate human T cell responses via expression of IDO. 
Our data showed that airway ECs could suppress antigen-
specific and non-specific T cell activation (i.e., T cell 
proliferation and IFN-γ production). Furthermore, the 
levels of T cell activation were partially recovered when 
ECs were exposed to different TLR agonists as mimics 
for bacterial and viral infections. Such reduction in the 
immune-suppressive effect of ECs after stimulation with 
bacterial and viral products could be crucial for facilitating 
the development of appropriate inflammatory responses 
for containing the infection.
Figure 4: Down-regulation of indoleamine 2,3-dioxygenase (IDO) in response to LPS stimulation in human primary 
bronchial epithelial cells (HBECs) and cell lines. A. and B. primary HBECs (n = 3) and HBEC line (BEAS-2B, n = 5) were 
incubated with increasing concentrations of E. coli LPS for 24 h, respectively, and IDO activity was assessed. (C and D) IDO1 gene 
expression in response to stimulation with 2 µg/ml and 0.1 µg/ml of LPS in primary HBECs and BEAS-2B, respectively (n = 3). Data 
represent the mean values ± SEM. **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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IDO is the TRP-depleting enzyme in the KYN 
pathway and has been extensively associated with 
modulating immune responses. DCs are one of the main 
producers of IDO-derived metabolites in the immune 
system [17, 18]; however, over the last decade ECs have 
also emerged as key players in modulating immune 
responses in the airways. Upon stimulation with allergens, 
airway ECs are able to produce a wide range of innate 
mediators that can activate other immune cells, including 
DCs, basophils and innate lymphoid cells. In addition, 
ECs express functional IDO after stimulation with pro-
inflammatory cytokines such as IFN-γ and TNF-α [23, 24, 
26-29]. 
It is widely recognised that IDO is constitutively 
expressed by many tumors as well as by infiltrating 
leucocytes present within the tumor microenvironment 
[34-36]. IDO is enzymatically active in human 
cancerous cell lines and creates an immunosuppressive 
microenvironment via TRP depletion and by formation 
of immunosuppressive IDO metabolites [37, 38]. In 
tumor state, high IDO expression and activity provides 
systemic tolerance via inhibition of the effector T cell 
infiltration [34, 39] and induction of Treg formation [40]. 
In addition, IDO could promote tumor cell survival and 
motility via production of endogeneuos KYN that drive 
the activation of aryl hydrocarbon receptor in cancer 
cells [16]. It has been reported that induction of IDO 
via IFN-γ provides anti-tumor effector mechanism in 
diverse human cancer cell lines including epithelial cell 
lines through the inhibition of their proliferation via TRP 
starvation [41]. Taken together, it is evident that elevated 
level of IDO in tumor environment could provide local 
and systemic immune suppression to facilitate immune 
escape by cancer cells [35]. Here in this study, we show 
for the first time that human airway ECs constitutively 
express IDO under resting conditions and critically there 
is significant down-regulation of IDO activity in both 
primary ECs and the cell lines in response to a wide 
Figure 5: Diverse TLR ligands and allergen extracts decreased indoleamine 2,3-dioxygenase (IDO) expression in 
human airway epithelial cells (ECs). A. Airway ECs (Calu-3) were incubated with 10 µg/ml of different TLR ligands and allergen 
extracts for 24 h (n ≥ 3). B. Primary human bronchial ECs were incubated with 2 µg/ml LPS, 10 µg/ml CpG, and 10 µg/ml allergen extracts 
(n = 3). C. Calu-3 ECs were treated with 10 µg/ml LPS, 10 g/ml polyribocytidylic acid (PolyI:C), or 10 g/ml CpG for 24 h, and IDO1 
protein levels were assessed in cell lysates by western blot analysis; GAPDH was used as a control (n = 3). Observed band sizes were 
45 kDa for IDO1 and 36 kDa for GAPDH, as predicted. HDM, house dust mite; BGP, Bermuda grass pollen; PEA, peanut; GC, German 
cockroach. Data represent the mean values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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range of TLR ligands and allergen extracts. Although 
the basal level of KYN production by primary human 
bronchial epithelial cells was lower (~3-6 µM) than that 
in BEAS-2B or Calu-3 cell lines (~20-40 µM) both cell 
types were similarly susceptible to stimulation with TLR 
ligands and allergens. Previous studies have suggested 
nitric oxide (NO) can inhibit IDO activity and expression 
[26, 42] most likely through post-translational regulation 
leading to proteasomal degradation of IDO rather than 
transcriptional regulation [26]. Down-regulation in IDO 
protein levels has also been observed in DCs through IL-6 
mediated proteasomal degradation [43, 44]. Since our data 
show significant transcriptional changes in IDO levels in 
ECs, hence it is reasonable to assume that the observed 
transcriptional changes in IDO in our experiments are 
unlikely to be due to changes in IL-6 or NO levels, 
and rather involve activation of intracellular signaling 
pathways that ultimately modulate IDO gene expression. 
Indeed this is in line with our observation showing no 
changes in IL-6 levels in all our experimental conditions 
(data not shown). 
Interestingly, the down-regulation of IDO in 
response to these stimuli in ECs is in contrast to the 
responses previously observed in DCs and macrophages 
[21, 45, 46], in which IDO activity is generally up-
regulated. This finding thus highlights the complexity of 
IDO regulation and fundamental differences in its activity 
between different cell types. It is reasonable to suggest that 
the constitutive expression of IDO by ECs under steady-
state conditions is associated with their ability to suppress 
unwanted immune reactions and to maintain immune 
homeostasis in the airways. In the context of cancerous 
cell lines, the high level of IDO activity contributes to the 
immunosuppressive tumor environment. However, after 
encountering pathogens (i.e., TLR engagement) and/or 
allergens (i.e., TLR or C-type lectin engagement), this 
regulatory mechanism could be disrupted through down-
regulation of IDO activity, which in turn could lead to 
increased T cell activity and subsequent immune responses 
to combat the infection. 
Previous studies have shown the importance of IDO 
from ECs during viral, bacterial, and parasite infections 
[26, 28, 31, 47-53]. Moreover, increased susceptibility 
to infection has been associated with the development 
of asthma-related diseases [54]. Accordingly, it would 
be interesting to explore the role of IDO and specific 
IDO-derived metabolites from airway ECs in modulating 
other immune and non-immune cells in the context of 
Figure 6: Role of indoleamine 2,3-dioxygenase (IDO)-expressing airway epithelial cells (ECs) on inhibition of PBMCs 
activation. A. Human airway ECs were transfected for 6 h with 50 nM of IDO1 small interfering RNA (siRNA) using a non-targeting 
siRNA as a negative control. The efficiency of IDO downregulation after transfection was assessed by evaluation of IDO activity and 
IDO1 mRNA expression (n = 3). B. Control ECs (i.e., IDOhigh) and IDOlow-ECs were co-cultured with anti-CD3-activated PBMCs. After 
three days, proliferation was assessed (n = 4). C. IFN-γ levels in the culture supernatants were quantified after 24 h and 48 h (n = 3). Data 
represent the mean values ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant.
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respiratory infection. 
We further evaluated the direct role of IDO in ECs 
in modulating T cell activation by generating IDOlow-
ECs using gene silencing. We found that knocking down 
IDO activity in ECs significantly reduced their ability 
to suppress T cell proliferation and IFN-γ production, 
suggesting an important role for IDO in this process. This 
effect is likely to be driven by a reduction in the level 
of IDO metabolites such as KYN and 3-HAA which are 
thought to drive most of the IDO-immune-suppressive 
effects [20, 55-60] however the exact mechanism is yet 
to be elucidated. It is also important to emphasize that the 
effects of IDO metabolites produced by ECs may not be 
limited to T cells, and might also modulate the function 
of other immune cells (e.g. basophils, and mast cells), 
broadening their overall immune modulatory effect. 
Future work should explore such possibilities. 
In conclusion, our results underline the important 
role of airway ECs in controlling immune responses 
through direct modulation of T cell function via 
production of IDO. Given the pivotal role of IDO-derived 
metabolites from DCs in modulating immune responses 
in the airways [21, 61-64] and the evidence pointing to 
a key role of EC-derived cytokines in modulating DC 
behavior [54], it would be interesting to study the effect 
of the IDO pathway on the cross-talk between DCs and 
ECs in the context of inflammatory conditions affecting 
the airways. This would help to better understand several 
airway-related pathologies such as allergic asthma and 
respiratory infections, leading to the development of 
improved therapeutic strategies to combat deleterious 
inflammatory responses in the airways. 
MAterIAls And MetHods
lung epithelial cells
Calu-3 cells (ATCC® HTB55™, a human lung 
epithelial adenocarcinoma cell line) were maintained in 
DMEM-Ham’s Nutrient Mixture F-12 (DMEM-F12; 
Sigma-Aldrich, St. Louis, MO, USA) containing 10% 
v/v heat-inactivated FBS, 100 U/ml penicillin-100 μg/
ml streptomycin (1% v/v pen/strep), 2 mM l-glutamine, 
and 1% v/v non-essential amino acid solution (Sigma-
Aldrich, St. Louis, MO, USA). BEAS-2B cells (ATTC® 
CRL-9609TM, a human bronchial epithelial cell line) were 
maintained in DMEM (Sigma-Aldrich, St. Louis, MO, 
USA) with 10% v/v heat-inactivated FBS, 100 U/ml 
penicillin-100 μg/ml streptomycin, and 2 mM l-glutamine. 
Primary human bronchial ECs were separated from the 
bronchial brushings (from healthy volunteers attending 
Nottingham University Hospital Respiratory Clinic 
after ethics committee approval and obtaining informed 
written consent) and were maintained in basal Bronchial 
Epithelial Growth Media supplemented with BEGM™ 
SingleQuots™ Kit (Clonetics™ Airway Epithelial Cell 
Systems, Lonza). 
PbMcs separation
PBMCs were isolated from fresh blood samples 
of healthy volunteers (obtained after receiving informed 
consent and local Ethics Committee approval) by density-
gradient centrifugation on Histopaque (Sigma-Aldrich, 
St. Louis, MO, USA). The cells were washed twice with 
PBS and 8 × 105 cells/600 µl were co-cultured with Calu-3 
cells in co-culture complete medium (1:1 ratio of DMEM-
F12:RPMI-1640; Sigma-Aldrich, St. Louis, MO, USA). 
Ido enzymatic activity assay
Calu-3 cells (2 × 105 cells/ml) were seeded in 
a 24-well plate supplemented with 100 μM l-TRP 
(Sigma-Aldrich, St. Louis, MO, USA), and grown to 
confluence for 24 h. Cells were stimulated with various 
TLR agonists and allergen extracts, including LPS and 
polyribocytidylic acid (polyI:C) (both from Sigma-
Aldrich, St. Louis, MO, USA), synthetic lipoprotein 
of Mycoplasma salivarium (FSL-1), CpG-ODN2216 
(5′-ggGGGACGA:TCGTCgggggg-3′) (both from 
Invivogen), house dust mite (Greer laboratories) extract 
and its purified allergen (Der p 1, Indoor Biotechnologies), 
Bermuda grass pollen, peanut, and German cockroach 
extracts (all from Greer laboratories). IDO activity was 
measured by quantification of kynurenines in the culture 
supernatant using a colorimetric assay as we have 
described previously [64]. 
Viability assay
Cell viability was quantified using the LIVE/DEAD 
viability/cytotoxicity kit and AlamarBlue assay (both from 
Invitrogen) as described previously [65, 66]. 
mrnA isolation, cdnA synthesis and Pcr
mRNA isolation and cDNA synthesis were 
performed using the μMACS one-step cDNA kit (Miltenyi 
Biotech) following the manufacturer instructions. PCR 
was carried out in a TC-312 PCR Thermocycler (Bibby 
Scientific Ltd.) using the Phusion Flash High-Fidelity PCR 
Master Mix (Thermo Scientific). IDO1 specific mRNA 
expression was quantified relative to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) expression using 
the following primers (Eurofins): GAPDH Forward 
(5′-GAGTCAACGGATTTGGTCGT-3′), GAPDH 
Reverse (5′-GACAAGCTTCCCGTTCTCAG-3′), IDO1 
Forward (5`-ACAGACCACAAGTCACAGCG-3′) and 
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IDO1 Reverse (5′-AACTGAGCAGCATGTCCTCC-3′). 
PCR products were analyzed on a 2% agarose gel 
electrophoresis system (Invitrogen, UK), visualized under 
UV light (Alpha Innotech Corporation), and the molecular 
weights of the bands were estimated with a standard 100-
bp Directload DNA ladder (Sigma-Aldrich, St. Louis, MO, 
USA).
Western blotting
Cells were washed with ice-cold PBS and then 
lysed using ice-cold radio-immunoprecipitation assay 
lysis buffer with protease and phosphatase inhibitor 
(Sigma-Aldrich, St. Louis, MO, USA) on a shaker for 30 
min at 4°C. Subsequently, cell lysates were centrifuged 
at 13,000 rpm for 30 min at 4°C. Supernatants were 
collected and stored at −20°C. Protein concentration 
was determined using the DC Protein Assay (Biorad) 
following the manufacturer’s protocol. The cell lysate 
was electrophoresed under reducing and denaturating 
conditions on a pre-cast 4-15% SDS-polyacrylamide gel 
(Biorad), and proteins were transferred to a nitrocellulose 
membrane (GE Healthcare). After a 2 h incubation in 
blocking buffer (5% non-fat milk in Tris-glycine buffer 
and 0.1% Tween 20), membranes were incubated with 
a primary rabbit monoclonal antibody [EPR1230Y] to 
IDO (Abcam, Cambridge, UK) overnight. After washing, 
the secondary peroxidase-conjugated antibody (goat 
anti-rabbit HRP) was added for 1 h. IDO was visualized 
using Amersham ECL prime Western Blotting Detection 
Reagents (GE Healthcare). GAPDH was used as a loading 
control with the rabbit monoclonal antibody (Abcam, 
Cambridge, UK). 
Gene silencing
Calu-3 cells were transfected with IDO1-
specific siRNA (GE Healthcare, UK) according to 
the manufacturer instructions. In brief, the cells were 
transfected on day one with 50 nM of IDO1 siRNA using 
a non-targeting siRNA as a negative control. The cells 
were then incubated for 6 h in complete medium without 
penicillin/streptomycin in a low-attachment tissue culture 
plate (Corning Life Sciences, Tewksbury, MA, USA) and 
then left for three days. The efficiency of IDO down-
regulation was assessed by an IDO activity quantitative 
assay as well as with conventional PCR for determination 
of IDO1 mRNA expression.
co-culture conditions
Control or IDOlow-ECs (6 × 105 cells/ml) were 
cultured in Transwells® with a 0.4 μm pore size (Scientific 
Laboratory Supplies Ltd.). After reaching confluence, 
PBMCs (8 × 105 cells/600 µl) were cultured in the 
bottom chamber in the presence of immobilized anti-
CD3 antibody (2 µg/ml) (Sigma-Aldrich, St. Louis, MO, 
USA) or 5 µg/ml of tuberculin purified protein derivate 
(Statens Serum Institute). In some experiments, the ECs 
were stimulated with TLR ligands. In addition, under 
certain conditions, IDO metabolites (KYN, 3-HAA and 
its vehicle) and HCl (all from Sigma-Aldrich, St. Louis, 
MO, USA) were added to the PBMCs. The cells were 
collected after 3-6 days for a BrdU proliferation assay and 
the supernatants were stored for cytokine analysis.
Proliferation assay
Cell proliferation was determined with the BrdU-
ELISA assay (Calbiochem, USA) according to the 
manufacturer instructions. 
cytokine measurements
Cytokine concentrations in the culture supernatants 
incubated for 24 h and 48 h were assessed using the 
DuoSet ELISA system for human IFN-γ (R&D Systems, 
UK) following the manufacturer instructions. 
statistical analysis
Data are expressed as mean values ± SEM. 
Statistical differences were determined using the Student 
t-test to compare two groups and using one-way ANOVA 
to compare three groups or more. Statistical significance 
was associated with p values < 0.05. 
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